HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ro 28-2653

a synthetic matrix metalloproteinase inhibitor reduces tumor growth and prolongs survival in a prostate cancer standard rat model
Also Known As:
5-biphenyl-4-yl-5-(4-(-nitro-phenyl)-piperazin-1-yl)-pyrimidine-2,4,6-trione; Ro-28-2653; Roche 28-2653
Networked: 10 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Krell, Hans-Willi: 6 articles (02/2007 - 03/2002)
2. Lein, Michael: 4 articles (02/2007 - 03/2002)
3. Jung, Klaus: 4 articles (02/2007 - 03/2002)
4. Loening, Stefan A: 3 articles (02/2007 - 02/2003)
5. Abramjuk, Claudia: 2 articles (02/2007 - 09/2005)
6. Rothaug, Winfried: 2 articles (02/2007 - 03/2002)
7. Juchem, Rolf: 2 articles (09/2005 - 03/2002)
8. Stephan, Carsten: 2 articles (09/2005 - 03/2002)
9. Schnorr, Dietmar: 2 articles (02/2003 - 03/2002)
10. Ortel, Bernhard: 2 articles (02/2003 - 03/2002)

Related Diseases

1. Neoplasms (Cancer)
2. Prostatic Neoplasms (Prostate Cancer)
3. Vascular Diseases (Vascular Disease)
4. Stroke (Strokes)
5. Adenocarcinoma

Related Drugs and Biologics

1. Matrix Metalloproteinases
2. Estramustine
3. Gelatinases
4. Etoposide (VP 16)
5. Doxycycline (Vibramycin)
6. batimastat (BB 94)
7. pyrimidine
8. diphenyl (biphenyl)
9. glucuronyl glucosamine glycan sulfate (Vessel)
10. Hormones

Related Therapies and Procedures

1. Lasers (Laser)
2. Induced Hyperthermia (Thermotherapy)